Technology

FDC / Fixed dose combination (Dry-coated tablets)

Success in complete separation and miniaturization of APIs: Development of formulation as a dry-coated tablet

Formulation design as a dry-coated tablet

• Complete separation to avoid interaction of the APIs
• Maintain the same formulation system of APIs as the single agent (BE)
• Miniaturization maintaining the strength of the formulation

A fixed dose combination of a proton pump inhibitor (Therapeutic agent for peptic ulcer) and a low-dose aspirin has been developed and launched as a FDC containing 100 mg of aspirin and 15 mg of a proton pump inhibitor in one tablet, and its usefulness including formulation characteristics is highly evaluated.